Glucotrack, Inc. — Form S-1

On July 14, 2026, Glucotrack completed a merger with Lokahi Therapeutics, creating a combined company with two operating subsidiaries: Glucotrack Technologies (medical devices for diabetes) and Lokahi (clinical-stage biopharmaceutical developing LT-100, a bee venom therapeutic for osteoarthritis and MS). The company simultaneously closed Bridge Financing ($7.95M), ELOC agreement (up to $50M over 3 years), Interim PIPE ($2M), and September PIPE ($4.5M cash, $4.5M exchange of prior notes), totaling ~$27.4M gross proceeds. Post-merger ownership: Lokahi stockholders hold ~90% on fully-diluted basis; pre-Closing Glucotrack stockholders hold ~10%. A 1-for-15 reverse stock split was implemented August 28, 2026.